Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1166-1176

  Sweeny, David J ^a   Li, Weiqun ^a   Clough, Jeffrey ^a   Bhamidipati, Somasekhar ^a   Singh, Rajinder ^a   Park, Gary ^a   Baluom, Muhammad ^a   Grossbard, Elliott ^a   Lau, David T W ^a  

^a RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; FOSTAMATINIB; GLUCURONIDE; N4 (2,2 DIMETHYL 3 OXO 4 PYRID[1,4]OXAZIN 6 YL) 5 FLUORO N2 (3,4,5 TRIMETHYOXYPHENYL) 2,4 PYRIMIDINEDIAMINE; PRODRUG; PROTEIN TYROSINE KINASE INHIBITOR; SULFATE; UNCLASSIFIED DRUG; N4-(2,2-DIMETHYL-3-OXO-4H-PYRID(1,4)OXAZIN-6-YL)-5-FLUORO-N2-(3,4,5-TRIMETHOXYPHENYL)-2,4-PYRIMIDINEDIAMINE; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; BIOTRANSFORMATION; DEMETHYLATION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SYNTHESIS; FECES; HUMAN; HYDROXYLATION; IN VITRO STUDY; INCUBATION TIME; INTESTINE; INTESTINE FLORA; LIVER; METABOLITE; PRIORITY JOURNAL; SPLEEN; URINE; ADULT; ANAEROBIC BACTERIUM; DRUG INACTIVATION; GASTROINTESTINAL TRACT; MALE; METABOLISM; MICROBIOLOGY; MICROSOME;

BACTERIA (MICROORGANISMS);

ADULT; BACTERIA, ANAEROBIC; BIOTRANSFORMATION; GASTROINTESTINAL TRACT; HUMANS; IN VITRO TECHNIQUES; INACTIVATION, METABOLIC; LIVER; MALE; MICROSOMES; OXAZINES; PRODRUGS; PYRIDINES;

EID: 77953742534     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032151     Document Type: Article

References (26)

1. Adlercreutz H (2007) Lignans and human health. Crit Rev Clin Lab Sci 44:483-525.
2. Berman MH and Frazer AC (1992) Importance of tetrahydrofolate and ATP in the anaerobic O-demethylation reaction for phenylmethylethers. Appl Environ Microbiol 58:925-931.
3. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, et al. (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319:998-1008.
4. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, et al. (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364.
5. Clavel T, Henderson G, Alpert CA, Philippe C, Rigottier-Gois L, Doré J, and Blaut M (2005) Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and enterolactone in humans. Appl Environ Microbiol 71:6077-6085.
6. Cocaign M, Wilberg E, and Lindley ND (1990) Sequential demethoxylation reactions during the methylotrophic growth of methoxylated aromatic substrates with Eubacterium limosum. Arch Microbiol 155:496-499.
7. Eeckhaut E, Struijs K, Possemiers S, Vincken JP, Keukeleire DD, and Verstraete W (2008) Metabolism of the lignan macromolecule into enterolignans in the gastrointestinal lumen as determined in the simulator of the human intestinal microbial ecosystem. J Agric Food Chem 56:4806-4812.
8. Engtrakul JJ, Foti RS, Strelevitz TJ, and Fisher MB (2005) Altered AZT (3′-azidio-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 33:1621-1627.
9. Fleisher D, Stewart BH and Amidon GL (1985) Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting, in Methods of Enzymology, vol 112 (Colowick N, Widder K, Kaplan N, and Green R, eds) pp 360-381, Elsevier, Maryland Heights, MO.
10. Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, and Spaltenstein A (2004) Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 48:791-798.
11. Heider J and Fuchs G (1997) Anaerobic metabolism of aromatic compounds. Eur J Biochem 243:577-596.
12. Lampe JW and Chang JL (2007) Interindividual differences in phytochemical metabolism and disposition. Semin Cancer Biol 17:347-353.
13. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
14. Mistry M and Houston JB (1987) Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 15:710-717.
15. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, and Brahn E (2007) Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 124:244-257.
16. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, and Bussel JB (2009) Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113:3154-3160.
17. Singh R and Masuda ES (2007) Spleen tyrosine kinase (SYK) biology, inhibitors and therapeutic applications. Annu Rep Med Chem 42:379-391.
18. Sweeny D, Li W, Grossbard E, and Lau D (2010) Contribution of gut bacteria to the metabolism of the Syk inhibitor R406 in cynomolgus monkey. Xenobiotica, in press.
19. Turner M, Schweighoffer E, Colucci F, Di Santo JP, and Tybulewicz VL(2000) Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 21:148-154. (Pubitemid 30122705)
20. Vierling P and Greiner J (2003) Prodrugs of HIV protease inhibitors. Curr Pharm Des 9:1755-1770.
21. Wang LQ, Meselhy MR, Li Y, Nakamura N, Min BS, Qin GW, and Hattori M (2001) The heterocyclic ring fission and dehydroxylation of catechins and related compounds by Eubacterium sp. strain SDG-2, a human intestinal bacterium. Chem Pharm Bull 49:1640-1643.
22. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, et al. (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebocontrolled trial. Arthritis Rheum 58:3309-3318.
23. Weinblatt ME, Kavanaugh A, Genovese M, Grossbard E, and Magilavy D (2009) Treatment of rheumatoid arthritis (RA) with an oral Syk kinase inhibitor: a 6 month randomized placebo controlled phase 2b study in patients with active RA on chronic methotrexate. Arthritis Rheum 60:3859-3860.
24. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
25. Wong BR, Grossbard EB, Payan DG, and Masuda ES (2004) Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13:743-762.
26. Zachariah PK and Juchau MR (1974) The role of gut flora in the reduction of aromatic nitro-groups. Drug Metab Dispos 2:74-78.